ANIP250117P55000
- 0.15
- 0.000.00%
ANI Pharmaceuticals Newsroom
Raymond James Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $83
ANI Pharmaceuticals (ANIP) Receives a Buy From Raymond James
Revenues Working Against ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Share Price
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?
Truist Financial Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating
Truist Financial Remains a Hold on ANI Pharmaceuticals (ANIP)
Alcami Announces Bill Humphries To Retire; Board Chair And Former Chief Executive Officer Patrick Walsh Will Serve As Interim CEO
Press Release: Alcami Announces CEO Transition
ANI Pharmaceuticals | 8-K: ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
ANI Pharmaceuticals Sees FY25 Revenue $739M-$759M, Consensus $720.3M
ANI Pharmaceuticals Affirms 2024 Guidance and Provides Preliminary Outlook for 2025
ANI Pharma Expects Q4 Purified Cortrophin Gel Revenues of $59.2M-$59.8M And $197.8M-$198.4M For FY24, Q4 ILUVIEN And YUTIQ Revenues Of $26.6M-$27.2M, FY25 Total Revenue Of $739M-$759M
Express News | ANI Pharmaceuticals Inc - Affirms 2024 Guidance, Provides 2025 Outlook
ANI Pharmaceuticals Sees 2025 Rev $739M-$759M >ANIP
Press Release: ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
ANI Pharmaceuticals Launches Generic Version of Motegrity
Express News | ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets With 180-Day Cgt Exclusivity
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Ani Pharmaceuticals Insider Sold Shares Worth $418,425, According to a Recent SEC Filing